594 results on '"Martinón Torres F"'
Search Results
2. Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008–2018
- Author
-
Pumarola, T., Díez-Domingo, J., Martinón-Torres, F., Redondo Margüello, E., de Lejarazu Leonardo, R. Ortiz, Carmo, M., Bizouard, G., Drago, G., López-Belmonte, J. L., Bricout, H., de Courville, C., and Gil-de-Miguel, A.
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study
- Author
-
Martinón-Torres, F., Carmo, M., Platero, L., Drago, G., López-Belmonte, J. L., Bangert, M., Díez-Domingo, J., and Garcés-Sánchez, M.
- Published
- 2022
- Full Text
- View/download PDF
4. Vacunación frente a la neumonía adquirida en la comunidad del adulto. Actualización 2021 del posicionamiento del Grupo de Neumoexpertos en Prevención
- Author
-
Redondo, E., Rivero-Calle, I., Mascarós, E., Yuste, J.E., Fernández-Prada, M., Ocaña, D., Jimeno, I., Gil, A., Molina, J., Díaz-Maroto, J.L., Linares, M., and Martinón-Torres, F.
- Published
- 2021
- Full Text
- View/download PDF
5. Recent advances in the prevention of meningococcal B disease: Real evidence from 4CMenB vaccination
- Author
-
Martinón-Torres, F., Banzhoff, A., Azzari, C., de Wals, P., Marlow, R., Marshall, H., Pizza, M., Rappuoli, R., and Bekkat-Berkani, R.
- Published
- 2021
- Full Text
- View/download PDF
6. Avances recientes en la prevención de la enfermedad meningocócica B: evidencia real de la vacunación con 4CMenB
- Author
-
Martinón-Torres, F., Banzhoff, A., Azzari, C., de Wals, P., Marlow, R., Marshall, H., Pizza, M., Rappuoli, R., and Bekkat-Berkani, R.
- Published
- 2021
- Full Text
- View/download PDF
7. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
- Author
-
Sánchez Luna, Manuel Ramón, Burgos Pol, R., Oyagüez, I., Figueras Aloy, J., Sánchez Solís, M., Martinón Torres, F., Carbonell Estrany, X., Sánchez Luna, Manuel Ramón, Burgos Pol, R., Oyagüez, I., Figueras Aloy, J., Sánchez Solís, M., Martinón Torres, F., and Carbonell Estrany, X.
- Abstract
Background: This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods: A decision-tree model was developed to compare health benefits (Quality Adjusted Life Years-QALYs) and costs of palivizumab versus a non-prophylaxis strategy over 6 years. A hypothetical cohort of 1,000 preterm infants, 32day 1-35day 0 wGA (4.356 kg average weight) at the beginning of the prophylaxis (15 mg/kg of palivizumab; 3.88 average number of injections per RSV season) was analysed. The model considered the most recent evidence from Spanish observational and epidemiological studies on RSV infection: the FLIP II study provided hospital admission and Intensive Care Unit (ICU) admission rates; in-hospital mortality rate was drawn from an epidemiological study from 2004 to 2012; recurrent wheezing rates associated to RSV infection from SPRING study were adjusted by the evidence on the palivizumab effect from clinical trials. Quality of life baseline value, number of hospitalized infants and the presence of recurrent wheezing over time were granted to estimate QALYs. National Health Service and societal perspective (included also recurrent wheezing indirect cost) were analysed. Total costs (€, 2016) included pharmaceutical and administration costs, hospitalization costs and recurrent wheezing management annual costs. A discount rate of 3.0% was applied annually for both costs and health outcomes. Results: Over 6 years, the base case analysis showed that palivizumab was associated to an increase of 0. 0731 QALYs compared to non-prophylaxis. Total costs were estimated in €2,110.71 (palivizumab) and €671.68 (non-prophylaxis) from the National Health System (NHS) perspective, resulting in an incremental cost utility ratio (ICUR) of €19,697.69/QALYs gained (prophylaxis vs non-prophylaxis). Results derived from the risk-factors popula, Depto. de Salud Pública y Materno - Infantil, Fac. de Medicina, TRUE, pub
- Published
- 2024
8. Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy
- Author
-
Gómez-Rial J, Rivero-Calle I, Salas A, and Martinón-Torres F
- Subjects
monocyte-macrophage ,covid-19 infection ,anti-gm-csf ,coronavirus ,Infectious and parasitic diseases ,RC109-216 - Abstract
Jose Gómez-Rial,1,2 Irene Rivero-Calle,1,3 Antonio Salas,1,4 Federico Martinón-Torres1,3 1Genetics, Vaccines, Infectious Diseases Research Group (GENVIP), Health Research Institute Santiago (IDIS), Hospital Clínico Universitario Santiago de Compostela (SERGAS), Galicia 15706, Spain; 2Immunology Laboratory, Clinical Laboratory, Hospital Clínico Universitario Santiago de Compostela (SERGAS), Galicia 15706, Spain; 3Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago De Compostela, Galicia 15706, Spain; 4Unidade de Xenética, Instituto de Ciencias Forenses (INCIFOR), Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, 15706, SpainCorrespondence: Jose Gómez-Rial Tel +34 981 950 379Email jose.gomez.rial@sergas.escov-Abstract: Emerging studies from SARS-CoV-2-infected patients indicate a preponderant role of monocytes/macrophages in the pathogenesis of this viral infection, in a similar way to that previously observed in other coronavirus outbreaks (SARS and MERS). The clinical presentation of severe patients resembles viral-associated hemophagocytic syndrome, a rare condition previously seen during lethal influenza pandemics and during previous SARS and MERS coronavirus outbreaks. SARS-CoV-2 infection triggers an over-exuberant inflammatory response due to the development of a cytokine storm and the depletion of the adaptative immune compartment, which may prelude sepsis in many cases. The present review summarizes past evidence on the role of monocytes/macrophages in previous coronavirus outbreaks and the emerging knowledge on their role in COVID-19 pathogenesis. Treatment strategies incorporating the blockade of migration and differentiation of monocyte-macrophage, such as granulocyte macrophage-colony stimulating factor inhibitors, might enhance the promising results seen so far with selective cytokine blockade.Keywords: monocyte/macrophage, COVID-19 infection, anti-GM-CSF, coronavirus
- Published
- 2020
9. Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
- Author
-
Rivero-Calle I, Raguindin PF, Gómez-Rial J, Rodriguez-Tenreiro C, and Martinón-Torres F
- Subjects
Meningococcal disease ,invasive meningococcal disease ,meningococcal B ,vaccine development ,vaccine effectiveness ,epidemiology ,Infectious and parasitic diseases ,RC109-216 - Abstract
Irene Rivero-Calle,1,2 Peter Francis Raguindin,2 Jose Gómez-Rial,2 Carmen Rodriguez-Tenreiro,2 Federico Martinón-Torres1,2 1Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Galicia, Spain; 2Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Hospital Clínico Universitario and Universidad de Santiago de Compostela (USC), Galicia, SpainCorrespondence: Federico Martinón-TorresTranslational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Travesía da Choupana, s/n, Santiago de Compostela 15706, SpainEmail Federico.Martinon.Torres@sergas.esAbstract: Invasive meningococcal disease (IMD) is a major public health concern because of its high case fatality, long-term morbidity, and potential to course with outbreaks. IMD caused by Nesseira meningitidis serogroup B has been predominant in different regions of the world like Europe and only recently broadly protective vaccines against B serogroup have become available. Two protein-based vaccines, namely 4CMenB (Bexsero®) and rLP2086 (Trumenba®) are currently licensed for use in different countries against MenB disease. These vaccines came from a novel technology on vaccine design (or antigen selection) using highly specific antigen targets identified through whole-genome sequence analysis. Moreover, it has the potential to confer protection against non-B meningococcus and against other Neisserial species such as gonococcus. Real-world data on the vaccine-use are rapidly accumulating from the UK and other countries which used the vaccine for control of outbreak or as part of routine immunization program, reiterating its safety and efficacy. Additional data on real-life effectiveness, long-term immunity, and eventual herd effects, including estimates on vaccine impact for cost-effectiveness assessment are further needed. Given the predominance of MenB in Europe and other parts of the world, these new vaccines are crucial for the prevention and public health control of the disease, and should be considered.Keywords: meningococcal disease, invasive meningococcal disease, meningococcal B, vaccine development, vaccine effectiveness, epidemiology
- Published
- 2019
10. Vacunación frente a la neumonía adquirida en la comunidad del adulto. Actualización 2018 del posicionamiento del Grupo de Neumoexpertos en Prevención
- Author
-
Redondo, E., Rivero-Calle, I., Vargas, D.A., Mascarós, E., Díaz-Maroto, J.L., Linares, M., Gil, A., Molina, J., Jimeno, I., Ocaña, D., Yuste, J.E., and Martinón-Torres, F.
- Published
- 2018
- Full Text
- View/download PDF
11. Rotavirus infection beyond the gut
- Author
-
Gómez-Rial J, Sánchez-Batán S, Rivero-Calle I, Pardo-Seco J, Martinón-Martínez JM, Salas A, and Martinón-Torres F
- Subjects
Rotavolution ,Extraintestinal ,Seizures ,Vaccines ,Autoimmunity ,Infectious and parasitic diseases ,RC109-216 - Abstract
José Gómez-Rial,1,2 Sonia Sánchez-Batán,2 Irene Rivero-Calle,1,3 Jacobo Pardo-Seco,1 José María Martinón-Martínez,1 Antonio Salas,1,4,5 Federico Martinón-Torres1,3 1Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain; 2Laboratorio de Inmunología, Servicio de Análisis Clínicos, Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain; 3Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain; 4Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forense, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, Galicia, Spain; 5GenPoB Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain Abstract: The landscape of rotavirus (RV) infection has changed substantially in recent years. Autoimmune triggering has been added to clinical spectrum of this pathology, which is now known to be much broader than diarrhea. The impact of RV vaccines in these other conditions is becoming a growing field of research. The importance of host genetic background in RV susceptibility has been revealed, therefore increasing our understanding of vaccine effectiveness and giving some clues about the limited efficacy of RV vaccines in low-income settings. Also, interaction of RV with intestinal microbiota seems to play a key role in the process of infection vaccine effect. This article reviews current findings on the extraintestinal impact of RV infection and their widening clinical picture, and the recently described mechanisms of host susceptibility to infection and vaccine effectiveness. RV infection is a systemic disease with clinical and pathophysiological implications beyond the gut. We propose an “iceberg” model for this pathology with almost hidden clinical implications away from the gastrointestinal tract and eventually triggering the development of autoimmune diseases. Impact of current vaccines is being influenced by host genetics and gut microbiota interactions and these factors must be taken into account in the development of public health programs. Keywords: rotavolution, extraintestinal, seizures, vaccines, autoimmunity
- Published
- 2018
12. Further considerations on rotavirus vaccination and seizure-related hospitalization rates
- Author
-
Gómez-Rial J, Sánchez-Batán S, Rivero-Calle I, Pardo-Seco J, Martinón-Martínez JM, Salas A, and Martinón-Torres F
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Jose Gómez-Rial,1,2 Sonia Sánchez-Batán,2 Irene Rivero-Calle,1,3 Jacobo Pardo-Seco,1 José María Martinón-Martínez,1 Antonio Salas,1,4–5 Federico Martinón-Torres1,31Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago de Compostela (SERGAS); 2Laboratorio de Inmunología, Servicio de Análisis Clínicos, Hospital Clínico Universitario de Santiago de Compostela (SERGAS); 3Pediatría Trasnlacional y Enfermedades Infecciossas, Departamento de Pediatría, Hospital Clínico Universitario de Santiago de Compostela (SERGAS); 4Unidade de Xenética, Instituto de Ciencias Forenses (INCIFOR), Facultade de Medicina, Universidade de Santiago de Compostela; 5GenPoB Research Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, SpainWe have read with interest the comments from Orrico-Sánchez et al1 regarding our recent paper on extraintestinal features of rotavirus (RV) infection.2 Their main concerns relate to the section dealing with the potential of RV vaccines to decrease hospitalizations due to seizures, and more specifically, the issues we raised in regards to their non-significant findings that might have been caused by the use of an overfitted statistical model.3 As our article was a general review beyond the relationship between RV and seizures, we did not have room for detailed explanations. We now take the opportunity to address Orrico-Sánchez et al's concerns.3This is in response to the Letter to the EditorView the original paper by Gómez-Rial and colleagues
- Published
- 2019
13. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018
- Author
-
Martinón-Torres, F., primary, Carmo, M., additional, Platero, L., additional, Drago, G., additional, López-Belmonte, JL., additional, Bangert, M., additional, and Díez-Domingo, J., additional
- Published
- 2023
- Full Text
- View/download PDF
14. Febrile illness in high-risk children: a prospective, international observational study.
- Author
-
Velden, F.J.S. van der, Vries, G de, Martin, A., Lim, E., Both, U. von, Kolberg, L., Carrol, E.D., Khanijau, A., Herberg, Jethro A., De, T., Galassini, R., Kuijpers, T.W., Martinón-Torres, F., Rivero-Calle, I., Vermont, C.L., Hagedoorn, N.N., Pokorn, M., Pollard, A.J., Schlapbach, L.J., Tsolia, M., Elefhteriou, I., Yeung, S., Zavadska, D., Fink, C., Voice, M., Zenz, W., Kohlmaier, B., Agyeman, P.K.A., Usuf, E., Secka, F., Groot, R. de, Levin, M., Flier, M. van der, Emonts, M., Velden, F.J.S. van der, Vries, G de, Martin, A., Lim, E., Both, U. von, Kolberg, L., Carrol, E.D., Khanijau, A., Herberg, Jethro A., De, T., Galassini, R., Kuijpers, T.W., Martinón-Torres, F., Rivero-Calle, I., Vermont, C.L., Hagedoorn, N.N., Pokorn, M., Pollard, A.J., Schlapbach, L.J., Tsolia, M., Elefhteriou, I., Yeung, S., Zavadska, D., Fink, C., Voice, M., Zenz, W., Kohlmaier, B., Agyeman, P.K.A., Usuf, E., Secka, F., Groot, R. de, Levin, M., Flier, M. van der, and Emonts, M.
- Abstract
01 februari 2023, Item does not contain fulltext, To assess and describe the aetiology and management of febrile illness in children with primary or acquired immunodeficiency at high risk of serious bacterial infection, as seen in emergency departments in tertiary hospitals. Prospective data on demographics, presenting features, investigations, microbiology, management, and outcome of patients within the 'Biomarker Validation in HR patients' database in PERFORM, were analysed. Immunocompromised children (< 18 years old) presented to fifteen European hospitals in nine countries, and one Gambian hospital, with fever or suspected infection and clinical indication for blood investigations. Febrile episodes were assigned clinical phenotypes using the validated PERFORM algorithm. Logistic regression was used to assess the effect size of predictive features of proven/presumed bacterial or viral infection. A total of 599 episodes in 482 children were analysed. Seventy-eight episodes (13.0%) were definite bacterial, 67 episodes probable bacterial (11.2%), and 29 bacterial syndrome (4.8%). Fifty-five were definite viral (9.2%), 49 probable viral (8.2%), and 23 viral syndrome (3.8%). One hundred ninety were unknown bacterial or viral infections (31.7%), and 108 had inflammatory or other non-infectious causes of fever (18.1%). Predictive features of proven/presumed bacterial infection were ill appearance (OR 3.1 (95% CI 2.1-4.6)) and HIV (OR 10.4 (95% CI 2.0-54.4)). Ill appearance reduced the odds of having a proven/presumed viral infection (OR 0.5 (95% CI 0.3-0.9)). A total of 82.1% had new empirical antibiotics started on admission (N = 492); 94.3% proven/presumed bacterial (N = 164), 66.1% proven/presumed viral (N = 84), and 93.2% unknown bacterial or viral infections (N = 177). Mortality was 1.9% (N = 11) and 87.1% made full recovery (N = 522). Conclusion: The aetiology of febrile illness in immunocompromised children is diverse. In one-third of cases, no cause for the fever will be identified. Justification for standard
- Published
- 2023
15. Diagnosis of childhood febrile illness using a multi-class blood RNA molecular signature.
- Author
-
Habgood-Coote, D., Wilson, C., Shimizu, C., Barendregt, A.M., Philipsen, R., Galassini, R., Calle, I.R., Workman, L., Agyeman, P.K.A., Ferwerda, G., Anderson, S.T., Berg, J.M. van den, Emonts, M., Carrol, E.D., Fink, C.G., Groot, R. de, Hibberd, M.L., Kanegaye, J., Nicol, M.P., Paulus, S., Pollard, A.J., Salas, A., Secka, F., Schlapbach, L.J., Tremoulet, A.H., Walther, M., Zenz, W., Flier, M. van der, Zar, H.J., Kuijpers, T., Burns, J.C., Martinón-Torres, F., Wright, V.J., Coin, L.J.M., Cunnington, A.J., Herberg, Jethro A., Levin, M., Kaforou, M., Habgood-Coote, D., Wilson, C., Shimizu, C., Barendregt, A.M., Philipsen, R., Galassini, R., Calle, I.R., Workman, L., Agyeman, P.K.A., Ferwerda, G., Anderson, S.T., Berg, J.M. van den, Emonts, M., Carrol, E.D., Fink, C.G., Groot, R. de, Hibberd, M.L., Kanegaye, J., Nicol, M.P., Paulus, S., Pollard, A.J., Salas, A., Secka, F., Schlapbach, L.J., Tremoulet, A.H., Walther, M., Zenz, W., Flier, M. van der, Zar, H.J., Kuijpers, T., Burns, J.C., Martinón-Torres, F., Wright, V.J., Coin, L.J.M., Cunnington, A.J., Herberg, Jethro A., Levin, M., and Kaforou, M.
- Abstract
Contains fulltext : 296516.pdf (Publisher’s version ) (Open Access), BACKGROUND: Appropriate treatment and management of children presenting with fever depend on accurate and timely diagnosis, but current diagnostic tests lack sensitivity and specificity and are frequently too slow to inform initial treatment. As an alternative to pathogen detection, host gene expression signatures in blood have shown promise in discriminating several infectious and inflammatory diseases in a dichotomous manner. However, differential diagnosis requires simultaneous consideration of multiple diseases. Here, we show that diverse infectious and inflammatory diseases can be discriminated by the expression levels of a single panel of genes in blood. METHODS: A multi-class supervised machine-learning approach, incorporating clinical consequence of misdiagnosis as a "cost" weighting, was applied to a whole-blood transcriptomic microarray dataset, incorporating 12 publicly available datasets, including 1,212 children with 18 infectious or inflammatory diseases. The transcriptional panel identified was further validated in a new RNA sequencing dataset comprising 411 febrile children. FINDINGS: We identified 161 transcripts that classified patients into 18 disease categories, reflecting individual causative pathogen and specific disease, as well as reliable prediction of broad classes comprising bacterial infection, viral infection, malaria, tuberculosis, or inflammatory disease. The transcriptional panel was validated in an independent cohort and benchmarked against existing dichotomous RNA signatures. CONCLUSIONS: Our data suggest that classification of febrile illness can be achieved with a single blood sample and opens the way for a new approach for clinical diagnosis. FUNDING: European Union's Seventh Framework no. 279185; Horizon2020 no. 668303 PERFORM; Wellcome Trust (206508/Z/17/Z); Medical Research Foundation (MRF-160-0008-ELP-KAFO-C0801); NIHR Imperial BRC.
- Published
- 2023
16. Are children with prolonged fever at a higher risk for serious illness? A prospective observational study.
- Author
-
Nijman, R.G., Tan, C.D., Hagedoorn, N.N., Nieboer, D., Herberg, Jethro A., Balode, A., Both, U. von, Carrol, E.D., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Kohlmaier, B., Lim, E., Martinón-Torres, F., Pokorn, M., Strle, F., Tsolia, M., Yeung, S., Zachariasse, J.M., Zavadska, D., Zenz, W., Levin, M., Vermont, C.L., Moll, H.A., Maconochie, I.K., Nijman, R.G., Tan, C.D., Hagedoorn, N.N., Nieboer, D., Herberg, Jethro A., Balode, A., Both, U. von, Carrol, E.D., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Kohlmaier, B., Lim, E., Martinón-Torres, F., Pokorn, M., Strle, F., Tsolia, M., Yeung, S., Zachariasse, J.M., Zavadska, D., Zenz, W., Levin, M., Vermont, C.L., Moll, H.A., and Maconochie, I.K.
- Abstract
01 augustus 2023, Contains fulltext : 294977.pdf (Publisher’s version ) (Closed access), OBJECTIVES: To describe the characteristics and clinical outcomes of children with fever ≥5 days presenting to emergency departments (EDs). DESIGN: Prospective observational study. SETTING: 12 European EDs. PATIENTS: Consecutive febrile children <18 years between January 2017 and April 2018. INTERVENTIONS: Children with fever ≥5 days and their risks for serious bacterial infection (SBI) were compared with children with fever <5 days, including diagnostic accuracy of non-specific symptoms, warning signs and C-reactive protein (CRP; mg/L). MAIN OUTCOME MEASURES: SBI and other non-infectious serious illness. RESULTS: 3778/35 705 (10.6%) of febrile children had fever ≥5 days. Incidence of SBI in children with fever ≥5 days was higher than in those with fever <5 days (8.4% vs 5.7%). Triage urgency, life-saving interventions and intensive care admissions were similar for fever ≥5 days and <5 days. Several warning signs had good rule in value for SBI with specificities >0.90, but were observed infrequently (range: 0.4%-17%). Absence of warning signs was not sufficiently reliable to rule out SBI (sensitivity 0.92 (95% CI 0.87-0.95), negative likelihood ratio (LR) 0.34 (0.22-0.54)). CRP <20 mg/L was useful for ruling out SBI (negative LR 0.16 (0.11-0.24)). There were 66 cases (1.7%) of non-infectious serious illnesses, including 21 cases of Kawasaki disease (0.6%), 28 inflammatory conditions (0.7%) and 4 malignancies. CONCLUSION: Children with prolonged fever have a higher risk of SBI, warranting a careful clinical assessment and diagnostic workup. Warning signs of SBI occurred infrequently but, if present, increased the likelihood of SBI. Although rare, clinicians should consider important non-infectious causes of prolonged fever.
- Published
- 2023
17. Vacunación frente a la neumonía adquirida en la comunidad del adulto. Posicionamiento del Grupo de Neumoexpertos en Prevención
- Author
-
Redondo, E., Rivero, I., Vargas, D.A., Mascarós, E., Díaz-Maroto, J.L., Linares, M., Valdepérez, J., Gil, A., Molina, J., Jimeno, I., Ocaña, D., and Martinón-Torres, F.
- Published
- 2016
- Full Text
- View/download PDF
18. A Respiratory Syncytial Virus (RSV) Prefusion F Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults≥60 Years of Age (YOA)
- Author
-
Ison, M, additional, Papi, A, additional, Langley, J, additional, Lee, D, additional, Leroux-Roels, I, additional, Martinón-Torres, F, additional, Schwarz, T, additional, van Zyl-smit, R, additional, Dezutter, N, additional, de Schrevel, N, additional, Fissette, L, additional, David, M, additional, Van Der Wielen, M, additional, Kostanyan, L, additional, and Hulstrøm, V, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Additional file 1 of Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008–2018
- Author
-
Pumarola, T., Díez-Domingo, J., Martinón-Torres, F., Redondo Margüello, E., de Lejarazu Leonardo, R. Ortiz, Carmo, M., Bizouard, G., Drago, G., López-Belmonte, J. L., Bricout, H., de Courville, C., and Gil-de-Miguel, A.
- Abstract
Additional file 1. Table S1. Diagnostic codes used to identify comorbidities/risk factors for influenza: a) in people ≥ 5 years old; b) in children < 5 years old. Table S2. Performance of the excess hospitalization model per age group and cause. Table S3. Performance of the excess deaths model per age group and cause. Table S4. Estimated influenza-associated excess pneumonia or influenza, respiratory, and all-cause excess hospitalizations, in absolute and per 100,000 people, by age group and epidemic season in Spanish public hospitals between 2008/2009 and 2017/2018. Table S5. Estimated influenza-associated excess pneumonia or influenza, respiratory, and respiratory or cardiovascular deaths, in absolute and per 100,000 people, by age group and epidemic season in Spain between 2008/2009 and 2017/2018. Table S6. P-value associated to the ILI variables of estimated influenza-associated excess hospitalization. Table S7. P-value associated to the ILI variables of estimated influenza-associated excess deaths.
- Published
- 2023
- Full Text
- View/download PDF
20. Additional file 1 of Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018
- Author
-
Martinón-Torres, F., Carmo, M., Platero, L., Drago, G., López-Belmonte, JL., Bangert, M., and Díez-Domingo, J.
- Abstract
Additional file 1: Listing S1. List of analyzed comorbidities and ICD9/10 codes used. Listing S2. List of ICD-9-MC and ICD-10-ES codes used as “severity markers”. Listing S3. Evolution in the incidence rate of hospitalizations by respiratory syncytial virus definition and age group.
- Published
- 2023
- Full Text
- View/download PDF
21. Correction to: Febrile illness in high-risk children: a prospective, international observational study
- Author
-
Van der Velden, FJS, De Vries, G, Martin, A, Lim, E, Von Both, U, Kolberg, L, Carrol, ED, Khanijau, A, Herberg, JA, De, T, Galassini, R, Kuijpers, TW, Martinón-Torres, F, Rivero-Calle, I, Vermont, CL, Hagedoorn, NN, Pokorn, M, Pollard, AJ, Schlapbach, LJ, Tsolia, M, Elefhteriou, I, Yeung, S, Zavadska, D, Fink, C, Voice, M, Zenz, W, Kohlmaier, B, Agyeman, PKA, Usuf, E, Secka, F, De Groot, R, Levin, M, Van der Flier, M, Emonts, M, and PERFORM consortium
- Subjects
Pediatrics, Perinatology and Child Health ,610 Medicine & health ,610 Medizin und Gesundheit - Published
- 2023
- Full Text
- View/download PDF
22. Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomics
- Author
-
Gómez-Carballa, A., primary, Pardo-Seco, J., additional, Pischedda, S., additional, Rivero-Calle, I., additional, Butler-Laporte, G., additional, Richards, J.B., additional, Viz-Lasheras, S., additional, Martinón-Torres, F., additional, and Salas, A., additional
- Published
- 2022
- Full Text
- View/download PDF
23. Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia
- Author
-
Cebey-López, M., primary, Currás-Tuala, M. J., additional, Gómez-Rial, J., additional, Rivero-Calle, I., additional, Pardo-Seco, J., additional, Mendez-Gallart, R., additional, Pischedda, S., additional, Gómez-Carballa, A., additional, Barral-Arca, R., additional, Justicia-Grande, A., additional, Viz-Lasheras, S., additional, Rodríguez-Tenreiro, C., additional, Gómez, R., additional, Salas, A., additional, and Martinón-Torres, F., additional
- Published
- 2022
- Full Text
- View/download PDF
24. A 2-transcript host cell signature distinguishes viral from bacterial diarrhea and it is influenced by the severity of symptoms
- Author
-
Barral-Arca, R., Pardo-Seco, J., Martinón-Torres, F., and Salas, A.
- Published
- 2018
- Full Text
- View/download PDF
25. Shock Index in the early assessment of febrile children at the emergency department: a prospective multicentre study
- Author
-
Hagedoorn, N.N., Zachariasse, J.M., Borensztajn, D., Adriaansens, E., Both, U. von, Carrol, E.D., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Herberg, J.A., Kohlmaier, B., Lim, E., Maconochie, I., Martinón-Torres, F., Nijman, R.G., Pokorn, M., Rivero-Calle, I., Tsolia, M., Zavadska, D., Zenz, W., Levin, M., Vermont, C., Moll, H.A., Hagedoorn, N.N., Zachariasse, J.M., Borensztajn, D., Adriaansens, E., Both, U. von, Carrol, E.D., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Herberg, J.A., Kohlmaier, B., Lim, E., Maconochie, I., Martinón-Torres, F., Nijman, R.G., Pokorn, M., Rivero-Calle, I., Tsolia, M., Zavadska, D., Zenz, W., Levin, M., Vermont, C., and Moll, H.A.
- Abstract
Item does not contain fulltext, OBJECTIVE: (1) To derive reference values for the Shock Index (heart rate/systolic blood pressure) based on a large emergency department (ED) population of febrile children and (2) to determine the diagnostic value of the Shock Index for serious illness in febrile children. DESIGN/SETTING: Observational study in 11 European EDs (2017-2018). PATIENTS: Febrile children with measured blood pressure. MAIN OUTCOME MEASURES: Serious bacterial infection (SBI), invasive bacterial infection (IBI), immediate life-saving interventions (ILSIs) and intensive care unit (ICU) admission. The association between high Shock Index (>95th centile) and each outcome was determined by logistic regression adjusted for age, sex, referral, comorbidity and temperature. Additionally, we calculated sensitivity, specificity and negative/positive likelihood ratios (LRs). RESULTS: Of 5622 children, 461 (8.2%) had SBI, 46 (0.8%) had IBI, 203 (3.6%) were treated with ILSI and 69 (1.2%) were ICU admitted. High Shock Index was associated with SBI (adjusted OR (aOR) 1.6 (95% CI 1.3 to 1.9)), ILSI (aOR 2.5 (95% CI 2.0 to 2.9)), ICU admission (aOR 2.2 (95% CI 1.4 to 2.9)) but not with IBI (aOR: 1.5 (95% CI 0.6 to 2.4)). For the different outcomes, sensitivity for high Shock Index ranged from 0.10 to 0.15, specificity ranged from 0.95 to 0.95, negative LRs ranged from 0.90 to 0.95 and positive LRs ranged from 1.8 to 2.8. CONCLUSIONS: High Shock Index is associated with serious illness in febrile children. However, its rule-out value is insufficient which suggests that the Shock Index is not valuable as a screening tool for all febrile children at the ED.
- Published
- 2022
26. Availability and use of rapid diagnostic tests for the management of acute childhood infections in Europe: A cross-sectional survey of paediatricians
- Author
-
Dewez, J.E., Pembrey, L., Nijman, R.G., Torso, S. Del, Grossman, Z., Hadjipanayis, A., Esso, D. Van, Lim, E., Emonts, M., Burns, J., Gras-LeGuen, C., Kohlfuerst, D., Dornbusch, H.J., Brengel-Pesce, K., Mallet, F., Both, U. von, Tsolia, M., Eleftheriou, I., Zavadska, D., Groot, R. de, Flier, M. van der, Moll, H., Hagedoorn, N., Borensztajn, D., Oostenbrink, R., Kuijpers, T., Pokorn, M., Vincek, K., Martinón-Torres, F., Rivero, I., Agyeman, P., Carrol, E.D., Paulus, S., Cunnington, A., Herberg, J., Levin, M., Mujkić, A., Geitmann, K., Dalt, L. Da, Valiulis, A., Lapatto, R., Syridou, G., Altorjai, P., Torpiano, P., Størdal, K., Illy, K., Mazur, A., Spreitzer, M.V., Rios, J. De Los, Wyder, C., Romankevych, I., Basmaci, R., Ibanez-Mico, S., Yeung, S., Dewez, J.E., Pembrey, L., Nijman, R.G., Torso, S. Del, Grossman, Z., Hadjipanayis, A., Esso, D. Van, Lim, E., Emonts, M., Burns, J., Gras-LeGuen, C., Kohlfuerst, D., Dornbusch, H.J., Brengel-Pesce, K., Mallet, F., Both, U. von, Tsolia, M., Eleftheriou, I., Zavadska, D., Groot, R. de, Flier, M. van der, Moll, H., Hagedoorn, N., Borensztajn, D., Oostenbrink, R., Kuijpers, T., Pokorn, M., Vincek, K., Martinón-Torres, F., Rivero, I., Agyeman, P., Carrol, E.D., Paulus, S., Cunnington, A., Herberg, J., Levin, M., Mujkić, A., Geitmann, K., Dalt, L. Da, Valiulis, A., Lapatto, R., Syridou, G., Altorjai, P., Torpiano, P., Størdal, K., Illy, K., Mazur, A., Spreitzer, M.V., Rios, J. De Los, Wyder, C., Romankevych, I., Basmaci, R., Ibanez-Mico, S., and Yeung, S.
- Abstract
Contains fulltext : 287630.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
27. Variation in CFHR3 determines susceptibility to meningococcal disease by controlling factor H concentrations
- Author
-
Kumar, Vikrant, Pouw, R.B., Autio, M.I., Sagmeister, M.G., Phua, Z. Yang, Borghini, L., Wright, V.J., Hoggart, C., Pan, B., Tan, A., Binder, A., Brouwer, M.C.T., Pinnock, E., Groot, R. de, Hazelzet, J., Emonts, M., Flier, M. van der, Reiter, K., Nöthen, M.M., Hoffmann, P., consortium, E., Schlapbach, L.J., Bellos, E., Anderson, S., Secka, F., Martinón-Torres, F., Salas, A., Fink, C., Carrol, E.D., Pollard, A.J., Coin, L.J., Zenz, W., Wouters, D., Ang, L. Teng, Hibberd, M.L., Levin, M., Kuijpers, T.W., Davila, S., Kumar, Vikrant, Pouw, R.B., Autio, M.I., Sagmeister, M.G., Phua, Z. Yang, Borghini, L., Wright, V.J., Hoggart, C., Pan, B., Tan, A., Binder, A., Brouwer, M.C.T., Pinnock, E., Groot, R. de, Hazelzet, J., Emonts, M., Flier, M. van der, Reiter, K., Nöthen, M.M., Hoffmann, P., consortium, E., Schlapbach, L.J., Bellos, E., Anderson, S., Secka, F., Martinón-Torres, F., Salas, A., Fink, C., Carrol, E.D., Pollard, A.J., Coin, L.J., Zenz, W., Wouters, D., Ang, L. Teng, Hibberd, M.L., Levin, M., Kuijpers, T.W., and Davila, S.
- Abstract
Contains fulltext : 282924.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
28. TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines
- Author
-
Rivero-Calle, I, Gómez-Rial, J, Bont, L, Gessner, BD, Kohn, M, Dagan, R, Payne, DC, Bruni, L, Pollard, AJ, García-Sastre, A, Faustman, DL, Osterhaus, A, Butler, R, Giménez Sánchez, F, Álvarez, F, Kaforou, M, Bello, X, and Martinón-Torres, F
- Subjects
Pharmacology ,Infectious disease ,Vaccination ,Immunology ,emergent virus ,off-target effects ,Meeting Report ,Communicable Diseases ,zoonoses ,transcriptomics ,vaccine-preventable diseases ,vaccine resilience ,Spain ,big data ,Respiratory Syncytial Virus, Human ,BCG Vaccine ,Animals ,Humans ,RNA gene signatures ,vaccine hesitancy ,Immunology and Allergy - Abstract
TIPICO is an expert meeting and workshop that aims to provide the most recent evidence in the field of infectious diseases and vaccination. The 10th Interactive Infectious Disease TIPICO workshop took place in Santiago de Compostela, Spain, on November 21–22, 2019. Cutting-edge advances in vaccination against respiratory syncytial virus, Streptococcus pneumoniae, rotavirus, human papillomavirus, Neisseria meningitidis, influenza virus, and Salmonella Typhi were discussed. Furthermore, heterologous vaccine effects were updated, including the use of Bacillus Calmette-Guérin (BCG) vaccine as potential treatment for type 1 diabetes. Finally, the workshop also included presentations and discussion on emergent virus and zoonoses, vaccine resilience, building and sustaining confidence in vaccination, approaches to vaccine decision-making, pros and cons of compulsory vaccination, the latest advances in decoding infectious diseases by RNA gene signatures, and the application of big data approaches.
- Published
- 2020
- Full Text
- View/download PDF
29. Additional file 1 of Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study
- Author
-
Martinón-Torres, F., Carmo, M., Platero, L., Drago, G., López-Belmonte, J. L., Bangert, M., Díez-Domingo, J., and Garcés-Sánchez, M.
- Abstract
Additional file 1: Table S1. List of analyzed risk factors andICD9/10 codes used. Table S2. Unit costs considered for each healthcare visit.
- Published
- 2022
- Full Text
- View/download PDF
30. A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018-19 season: the Gripómetro
- Author
-
Díez-Domingo J, Redondo Margüello E, Ortiz de Lejarazu Leonardo R, Gil de Miguel Á, Guillén Ortega JM, Rincón Mora J, and Martinón-Torres F
- Subjects
Vaccine coverage ,Surveillance ,Influenza vaccine ,Influenza - Abstract
ASBTRACT: BACKGROUND: Electronic vaccine registries are not yet widely established. There is a need to real-time monitor influenza vaccine coverage, which may raise awareness to risk groups and professionals, and eventually allow to adopt tailored measures during the vaccination campaign. To evaluate the utility of the "Gripómetro", a demographic study designed to monitor national and regional influenza vaccine coverage on a weekly basis in Spain. METHODS: Quantitative study based on surveys of the Spanish population between 18-80 years and a sample of primary care doctors and nurses randomly selected. Pre-proportional fixation has been established by Autonomous Communities and age group to guarantee the representativeness of all the autonomies. RESULTS: Interviews were conducted in 3400 households of general population and 807 respondents among health care professionals. We found that the results of influenza vaccination coverage in the population = 65 years obtained by the Gripómetro for 2018-2019 season were mostly comparable with the official data presented by the Ministry of Health after the end of the vaccination campaign. CONCLUSIONS: The Gripómetro is a robust research method that provides real-time data and trends for influenza vaccine coverage along with other useful information related to vaccination such as intention to vaccinate, motivation and barriers to vaccination.
- Published
- 2022
31. Vesiculobullous skin reactions induced by COVID‐19 mRNA vaccine: report of four cases and review of the literature
- Author
-
Coto‐Segura, P., primary, Fernández‐Prada, M., additional, Mir‐Bonafé, M., additional, García‐García, B., additional, González‐Iglesias, I., additional, Alonso‐Penanes, P., additional, González‐Guerrero, M., additional, Gutiérrez‐Palacios, A., additional, Miranda‐Martínez, E., additional, and Martinón‐Torres, F., additional
- Published
- 2021
- Full Text
- View/download PDF
32. High-dose trivalent influenza vaccine: safety and immunogenicity
- Author
-
Ortiz de Lejarazu R, Martinón Torres F, Gil de Miguel A, Díez Domingo J, and Redondo Marguello E
- Subjects
Vaccine safety ,High-dose influenza vaccine ,Elderly population ,Influenza vaccine ,Vaccine immunogenicity - Abstract
Adults aged 65 years or older suffer the most severe health effects of seasonal flu. Although the influenza vaccine is effective in preventing influenza virus infection and its complications, it is not as effective in the elderly due to age-associated immunosenescence phenomenon. Since 2009, a high-dose trivalent influenza vaccine has been approved in the United States for the immunization of people >= 65 years with an antigen concentration four times higher than the standard vaccine. Multiple clinical trials carried out over different seasons, and using different methodologies, have shown that the high-dose trivalent influenza vaccine is not only more effective, but it also has a similar safety profile and is more immunogenic than the standard dose vaccine in the prevention of flu and its complications in the elderly. This document reviews the current scientific evidence on the safety and immunogenicity of high-dose influenza vaccine in people aged 65 years and over, and includes information from randomized clinical trials, observational studies with data from real clinical practice, and systematic reviews, and meta-analysis.
- Published
- 2021
33. Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe-results from the PED-MERMAIDS multicentre case-control study
- Author
-
Vasconcelos, M.K. Loens, K. Sigfrid, L. Iosifidis, E. Epalza, C. Donà, D. Matheeussen, V. Papachristou, S. Roilides, E. Gijon, M. Rojo, P. Minotti, C. Da Dalt, L. Islam, S. Jarvis, J. Syggelou, A. Tsolia, M. Nyang'wa, M.N. Keers, S. Renk, H. Gemmel, A.-L. D'Amore, C. Atti, M.C.D. Sánchez, C.R.-T. Martinón-Torres, F. Burokiene, S. Goetghebuer, T. Spoulou, V. Riordan, A. Calvo, C. Gkentzi, D. Hufnagel, M. Openshaw, P.J. De Jong, M.D. Koopmans, M. Goossens, H. Ieven, M. Fraaij, P.L.A. Giaquinto, C. Bielicki, J.A. Horby, P. Sharland, M.
- Subjects
viruses ,respiratory tract diseases - Abstract
Background Both pathogenic bacteria and viruses are frequently detected in the nasopharynx (NP) of children in the absence of acute respiratory infection (ARI) symptoms. The aim of this study was to estimate the aetiological fractions for ARI hospitalisation in children for respiratory syncytial virus (RSV) and influenza virus and to determine whether detection of specific respiratory pathogens on NP samples was associated with ARI hospitalisation. Methods 349 children up to 5 years of age hospitalised for ARI (following a symptom-based case definition) and 306 hospital controls were prospectively enrolled in 16 centres across seven European Union countries between 2016 and 2019. Admission day NP swabs were analysed by multiplex PCR for 25 targets. Results RSV was the leading single cause of ARI hospitalisations, with an overall population attributable fraction (PAF) of 33.4% and high seasonality as well as preponderance in younger children. Detection of RSV on NP swabs was strongly associated with ARI hospitalisation (OR adjusted for age and season: 20.6, 95% CI: 9.4 to 45.3). Detection of three other viral pathogens showed strong associations with ARI hospitalisation: influenza viruses had an adjusted OR of 6.1 (95% CI: 2.5 to 14.9), parainfluenza viruses (PIVs) an adjusted OR of 4.6 (95% CI: 1.8 to 11.3) and metapneumoviruses an adjusted OR of 4.5 (95% CI: 1.3 to 16.1). Influenza viruses had a PAF of 7.9%, PIVs of 6.5% and metapneumoviruses of 3.0%. In contrast, most other pathogens were found in similar proportions in cases and controls, including Streptococcus pneumoniae, which was weakly associated with case status, and endemic coronaviruses. Conclusion RSV is the predominant cause of ARI hospitalisations in young children in Europe and its detection, as well as detection of influenza virus, PIV or metapneumovirus, on NP swabs can establish aetiology with high probability. PAFs for RSV and influenza virus are highly seasonal and age dependent. © 2016 Georg Thieme Verlag. All rights reserved.
- Published
- 2021
34. Development and validation of a prediction model for invasive bacterial infections in febrile children at European Emergency Departments: MOFICHE, a prospective observational study
- Author
-
Hagedoorn, N.N., Borensztajn, D., Nijman, R.G., Nieboer, D., Herberg, J.A., Balode, A., Both, U. von, Carrol, E., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Kohlmaier, B., Lim, E., Maconochie, I., Martinón-Torres, F., Pokorn, M., Strle, F., Tsolia, M., Zavadska, D., Zenz, W., Levin, M., Vermont, C., Moll, H.A., Hagedoorn, N.N., Borensztajn, D., Nijman, R.G., Nieboer, D., Herberg, J.A., Balode, A., Both, U. von, Carrol, E., Eleftheriou, I., Emonts, M., Flier, M. van der, Groot, R. de, Kohlmaier, B., Lim, E., Maconochie, I., Martinón-Torres, F., Pokorn, M., Strle, F., Tsolia, M., Zavadska, D., Zenz, W., Levin, M., Vermont, C., and Moll, H.A.
- Abstract
Contains fulltext : 235741.pdf (Publisher’s version ) (Open Access)
- Published
- 2021
35. Detectable A Disintegrin and Metalloproteinase With Thrombospondin Motifs-1 in Serum Is Associated With Adverse Outcome in Pediatric Sepsis
- Author
-
Boeddha, N.P., Driessen, G.J., Hagedoorn, N.N., Kohlfuerst, D.S., Hoggart, C.J., Rijswijk, A.L. van, Ekinci, E., Priem, D., Schlapbach, L.J., Herberg, J.A., Groot, R. de, Anderson, S.T., Fink, C.G., Carrol, E.D., Flier, M. van der, Martinón-Torres, F., Levin, M., Leebeek, F.W.G., Zenz, W., Maat, M.P. de, Hazelzet, Jan A., Emonts, M., Dik, W.A., Boeddha, N.P., Driessen, G.J., Hagedoorn, N.N., Kohlfuerst, D.S., Hoggart, C.J., Rijswijk, A.L. van, Ekinci, E., Priem, D., Schlapbach, L.J., Herberg, J.A., Groot, R. de, Anderson, S.T., Fink, C.G., Carrol, E.D., Flier, M. van der, Martinón-Torres, F., Levin, M., Leebeek, F.W.G., Zenz, W., Maat, M.P. de, Hazelzet, Jan A., Emonts, M., and Dik, W.A.
- Abstract
Contains fulltext : 241374.pdf (Publisher’s version ) (Open Access), IMPORTANCE: A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 is hypothesized to play a role in the pathogenesis of invasive infection, but studies in sepsis are lacking. OBJECTIVES: To study A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 protein level in pediatric sepsis and to study the association with outcome. DESIGN: Data from two prospective cohort studies. SETTING AND PARTICIPANTS: Cohort 1 is from a single-center study involving children admitted to PICU with meningococcal sepsis (samples obtained at three time points). Cohort 2 includes patients from a multicenter study involving children admitted to the hospital with invasive bacterial infections of differing etiologies (samples obtained within 48 hr after hospital admission). MAIN OUTCOMES AND MEASURES: Primary outcome measure was mortality. Secondary outcome measures were PICU-free days at day 28 and hospital length of stay. RESULTS: In cohort 1 (n = 59), nonsurvivors more frequently had A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels above the detection limit than survivors at admission to PICU (8/11 [73%] and 6/23 [26%], respectively; p = 0.02) and at t = 24 hours (2/3 [67%] and 3/37 [8%], respectively; p = 0.04). In cohort 2 (n = 240), A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels in patients within 48 hours after hospital admission were more frequently above the detection limit than in healthy controls (110/240 [46%] and 14/64 [22%], respectively; p = 0.001). Nonsurvivors more often had detectable A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels than survivors (16/21 [76%] and 94/219 [43%], respectively; p = 0.003), which was mostly attributable to patients with Neisseria meningitidis. CONCLUSIONS AND RELEVANCE: In children with bacterial infection, detection of A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 within 48 hours after hospital admission is associated with death, part
- Published
- 2021
36. Detectable A Disintegrin and Metalloproteinase With Thrombospondin Motifs-1 in Serum Is Associated With Adverse Outcome in Pediatric Sepsis.
- Author
-
Boeddha, NP, Driessen, GJ, Hagedoorn, NN, Kohlfuerst, DS, Hoggart, CJ, van Rijswijk, AL, Ekinci, E, Priem, D, Schlapbach, LJ, Herberg, JA, de Groot, R, Anderson, ST, Fink, CG, Carrol, ED, van der Flier, M, Martinón-Torres, F, Levin, M, Leebeek, FW, Zenz, W, de Maat, MPM, Hazelzet, JA, Emonts, M, Dik, WA, Boeddha, NP, Driessen, GJ, Hagedoorn, NN, Kohlfuerst, DS, Hoggart, CJ, van Rijswijk, AL, Ekinci, E, Priem, D, Schlapbach, LJ, Herberg, JA, de Groot, R, Anderson, ST, Fink, CG, Carrol, ED, van der Flier, M, Martinón-Torres, F, Levin, M, Leebeek, FW, Zenz, W, de Maat, MPM, Hazelzet, JA, Emonts, M, and Dik, WA
- Abstract
IMPORTANCE: A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 is hypothesized to play a role in the pathogenesis of invasive infection, but studies in sepsis are lacking. OBJECTIVES: To study A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 protein level in pediatric sepsis and to study the association with outcome. DESIGN: Data from two prospective cohort studies. SETTING AND PARTICIPANTS: Cohort 1 is from a single-center study involving children admitted to PICU with meningococcal sepsis (samples obtained at three time points). Cohort 2 includes patients from a multicenter study involving children admitted to the hospital with invasive bacterial infections of differing etiologies (samples obtained within 48 hr after hospital admission). MAIN OUTCOMES AND MEASURES: Primary outcome measure was mortality. Secondary outcome measures were PICU-free days at day 28 and hospital length of stay. RESULTS: In cohort 1 (n = 59), nonsurvivors more frequently had A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels above the detection limit than survivors at admission to PICU (8/11 [73%] and 6/23 [26%], respectively; p = 0.02) and at t = 24 hours (2/3 [67%] and 3/37 [8%], respectively; p = 0.04). In cohort 2 (n = 240), A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels in patients within 48 hours after hospital admission were more frequently above the detection limit than in healthy controls (110/240 [46%] and 14/64 [22%], respectively; p = 0.001). Nonsurvivors more often had detectable A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 levels than survivors (16/21 [76%] and 94/219 [43%], respectively; p = 0.003), which was mostly attributable to patients with Neisseria meningitidis. CONCLUSIONS AND RELEVANCE: In children with bacterial infection, detection of A Disintegrin and Metalloproteinase with Thrombospondin Motifs-1 within 48 hours after hospital admission is associated with death, part
- Published
- 2021
37. Cappric study—characterization of community-acquired pneumonia in spanish adults managed in primary care settings
- Author
-
Universitat Rovira i Virgili, Molina J; González-Gamarra A; Ginel L; Peláez ME; Juez JL; Artuñedo A; Aldana G; Quesada E; Cabré JJ; Gómez A; Linares M; Marín MT; Sanchez PY; Núñez L; Gonzálvez J; Mascarós E; López J; Cano A; Herrero J; Serra MC; Cimas E; Pedrol M; Alfaro JV; Martinón-Torres F; Cifuentes I; Méndez C; Ocaña D, Universitat Rovira i Virgili, and Molina J; González-Gamarra A; Ginel L; Peláez ME; Juez JL; Artuñedo A; Aldana G; Quesada E; Cabré JJ; Gómez A; Linares M; Marín MT; Sanchez PY; Núñez L; Gonzálvez J; Mascarós E; López J; Cano A; Herrero J; Serra MC; Cimas E; Pedrol M; Alfaro JV; Martinón-Torres F; Cifuentes I; Méndez C; Ocaña D
- Abstract
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. The real burden of community-acquired pneumonia (CAP) in non-hospitalized patients is largely unknown. This is a 3-year prospective, observational study of ambulatory CAP in adults, conducted in 24 Spanish primary care centers between 2016–2019. Sociodemographic and clinical variables of patients with radiographically confirmed CAP were collected. Pneumococcal etiology was assessed using the Binax Now® test. Patients were followed up for 10 ± 3 days. A total of 456 CAP patients were included in the study. Mean age was 56.6 (± 17.5) years, 53.5% were female, and 53.9% had ≥1 comorbidity. Average incidence of CAP was 1.2–3.5 cases per 1000 persons per year.
- Published
- 2021
38. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection
- Author
-
Gómez-Rial, J. and Martinón-Torres, F.
- Published
- 2020
- Full Text
- View/download PDF
39. Low Sensitivity of BinaxNOW RSV in Infants
- Author
-
Zuurbier, RP, Bont, LJ, Langedijk, AC, Hamer, M, Korsten, K, Drysdale, SB, Snape, MD, Robinson, H, Pollard, AJ, Martinón-Torres, F, Rodríguez-Tenreiro Sánchez, C, Gómez-Carballa, A, Dacosta-Urbieta, AI, Heikkinen, T, Cunningham, S, van Houten, MA, Wildenbeest, JG, and RESCEU Investigators
- Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis. METHODS: We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard. RESULTS: One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%). Sensitivity was low in all subgroups. CONCLUSIONS: We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.
- Published
- 2020
40. Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants
- Author
-
Lin, G-L, Golubchik, T, Drysdale, S, O'Connor, D, Jefferies, K, Brown, A, de Cesare, M, Bonsall, D, Ansari, MA, Aerssens, J, Bont, L, Openshaw, P, Martinón-Torres, F, Bowden, R, Pollard, AJ, and RESCEU Investigators
- Abstract
Targeted metagenomics using strand-specific libraries with target enrichment is a sensitive, generalized approach to pathogen sequencing and transcriptome profiling. Using this method, we recovered 13 (76%) complete human respiratory syncytial virus (RSV) genomes from 17 clinical respiratory samples, reconstructed the phylogeny of the infecting viruses, and detected differential gene expression between 2 RSV subgroups, specifically, a lower expression of the P gene and a higher expression of the M2 gene in RSV-A than in RSV-B. This methodology can help to relate viral genetics to clinical phenotype and facilitate ongoing population-level RSV surveillance and vaccine development. Clinical Trials Registration. NCT03627572 and NCT03756766.
- Published
- 2020
41. Genome-wide association study identifies risk variants for sporadic Creutzfeldt-Jakob disease in STX6 and GAL3ST1
- Author
-
Anna Poleggi, John Collinge, Carla A. Ibrahim-Verbaas, Jean-Philippe Brandel, Emma Jones, Dimitriadis A, Anna Bartoletti-Stella, James Uphill, Christiane Stehmann, Mok Th, Gerard H. Jansen, Tracy Campbell, Zafar S, Holger Hummerich, van Duijn C, Jiri G. Safar, Ewa Golanska, Martinón-Torres F, Aili Golubjatnikov, Michael B. Coulthart, Zane Jaunmuktane, Beata Sikorska, Giuseppe Matullo, Miguel Calero, Jerome Whitfield, Sabina Capellari, Jean-Louis Laplanche, Kathleen Glisic, Gabor G. Kovacs, Richard Knight, Helen Speedy, Juan Ps, Olga Calero, Jean-Charles Lambert, Stéphane Haïk, Anna Ladogana, Akin Nihat, Stephanie A. Booth, Serena Aneli, Herbert Budka, Pawel P. Liberski, Piero Parchi, Shannon Sarros, Jacqueline M. Linehan, Sebastian Brandner, Maurizio Pocchiari, Ahmed P, Michael D. Geschwind, Fronztek K, Antonio Salas, Inga Zerr, Janis Blevins, Elodie Bouaziz-Amar, Brian S. Appleby, Steven J. Collins, P. Gambetti, Hata Karamujić-Čomić, Adriano Aguzzi, Philippe Amouyel, van der Lee S, Penny Norsworthy, Parmjit S. Jat, Liam Quinn, Emmanuelle Viré, and Simon Mead
- Subjects
Genetics ,0303 health sciences ,biology ,animal diseases ,Tau protein ,STX6 ,Single-nucleotide polymorphism ,Genome-wide association study ,medicine.disease ,3. Good health ,Progressive supranuclear palsy ,PRNP ,nervous system diseases ,03 medical and health sciences ,0302 clinical medicine ,medicine ,biology.protein ,Gene ,030217 neurology & neurosurgery ,Exome sequencing ,030304 developmental biology - Abstract
Mammalian prions are lethal pathogens composed of fibrillar assemblies of misfolded prion protein. Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common being sporadic Creutzfeldt-Jakob disease (sCJD). Variants in the gene that encodes prion protein (PRNP) are strong risk factors for sCJD, but although the condition has heritability similar to other neurodegenerative disorders, no other risk loci have yet been confirmed. By genome-wide association in European ancestry populations, we found three replicated loci (cases n=5208, within PRNP, STX6, and GAL3ST1) and two further unreplicated loci were significant in gene-wide tests (within PDIA4, BMERB1). Exome sequencing in 407 sCJD cases, conditional and transcription analyses suggest that associations at PRNP and GAL3ST1 are likely to be caused by common variants that alter the protein sequence, whereas risk variants in STX6 and PDIA4 associate with increased expression of the major transcripts in disease-relevant brain regions. Alteration of STX6 expression does not modify prion propagation in a neuroblastoma cell model of mouse prion infection. We went on to analyse the proteins histologically in diseased tissue and examine the effects of risk variants on clinical phenotypes using deep longitudinal clinical cohort data. Risk SNPs in STX6, a protein involved in the intracellular trafficking of proteins and vesicles, are shared with progressive supranuclear palsy, a neurodegenerative disease associated with the misfolded protein tau. We present the first evidence of statistically robust associations in sporadic human prion disease that implicate intracellular trafficking and sphingolipid metabolism.
- Published
- 2020
- Full Text
- View/download PDF
42. Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood
- Author
-
Zandstra, J. van de Geer, A. Tanck, M.W.T. van Stijn-Bringas Dimitriades, D. Aarts, C.E.M. Dietz, S.M. van Bruggen, R. Schweintzger, N.A. Zenz, W. Emonts, M. Zavadska, D. Pokorn, M. Usuf, E. Moll, H.A. Schlapbach, L.J. Carrol, E.D. Paulus, S. Tsolia, M. Fink, C. Yeung, S. Shimizu, C. Tremoulet, A. Galassini, R. Wright, V.J. Martinón-Torres, F. Herberg, J. Burns, J. Levin, M. Kuijpers, T.W. EUCLIDS Consortium, PERFORM Consortium UK Kawasaki Disease Genetics Study Network
- Abstract
Background: Kawasaki disease (KD) is a vasculitis of early childhood mimicking several infectious diseases. Differentiation between KD and infectious diseases is essential as KD's most important complication—the development of coronary artery aneurysms (CAA)—can be largely avoided by timely treatment with intravenous immunoglobulins (IVIG). Currently, KD diagnosis is only based on clinical criteria. The aim of this study was to evaluate whether routine C-reactive protein (CRP) and additional inflammatory parameters myeloid-related protein 8/14 (MRP8/14 or S100A8/9) and human neutrophil-derived elastase (HNE) could distinguish KD from infectious diseases. Methods and Results: The cross-sectional study included KD patients and children with proven infections as well as febrile controls. Patients were recruited between July 2006 and December 2018 in Europe and USA. MRP8/14, CRP, and HNE were assessed for their discriminatory ability by multiple logistic regression analysis with backward selection and receiver operator characteristic (ROC) curves. In the discovery cohort, the combination of MRP8/14+CRP discriminated KD patients (n = 48) from patients with infection (n = 105), with area under the ROC curve (AUC) of 0.88. The HNE values did not improve discrimination. The first validation cohort confirmed the predictive value of MRP8/14+CRP to discriminate acute KD patients (n = 26) from those with infections (n = 150), with an AUC of 0.78. The second validation cohort of acute KD patients (n = 25) and febrile controls (n = 50) showed an AUC of 0.72, which improved to 0.84 when HNE was included. Conclusion: When used in combination, the plasma markers MRP8/14, CRP, and HNE may assist in the discrimination of KD from both proven and suspected infection. © Copyright © 2020 Zandstra, van de Geer, Tanck, van Stijn-Bringas Dimitriades, Aarts, Dietz, van Bruggen, Schweintzger, Zenz, Emonts, Zavadska, Pokorn, Usuf, Moll, Schlapbach, Carrol, Paulus, Tsolia, Fink, Yeung, Shimizu, Tremoulet, Galassini, Wright, Martinón-Torres, Herberg, Burns, Levin, Kuijpers, EUCLIDS Consortium, PERFORM Consortium and UK Kawasaki Disease Genetics Study Network.
- Published
- 2020
43. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons A Randomized Clinical Trial
- Author
-
Dbaibo G, Amanullah A, Claeys C, Izu A, Jain VK, Kosalaraksa P, Rivera L, Soni J, Yanni E, Zaman K, Acosta B, Ariza M, Arroba Basanta ML, Bavdekar A, Carmona A, Cousin L, Danier J, Diaz A, Diez-Domingo J, Dinleyici EC, Faust SN, Garcia-Sicilia J, Gomez-Go GD, Gonzales MLA, Hacimustafaoglu M, Hughes SM, Jackowska T, Kant S, Lucero M, Mares Bermudez J, Martinón-Torres F, Montellano M, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Szymanski H, Ulied A, Woo W, Schuind A, Innis BL, and Flu4VEC Study Group
- Subjects
seasonal variation ,healthcare utilization ,vaccine efficacy ,influenza ,disease attenuation - Abstract
Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6-35 months of age in a phase III, observer-blind trial. Methods: The aim of this analysis was to estimate vaccine efficacy (VE) in preventing laboratory-confirmed influenza in each of 5 independent seasonal cohorts (2011-2014), as well as vaccine impact on healthcare utilization in 3 study regions (Europe/Mediterranean, Asia-Pacific and Central America). Healthy children were randomized 1:1 to IIV4 or control vaccines. VE was estimated against influenza confirmed by reverse transcription polymerase chain reaction on nasal swabs. Cultured isolates were characterized as antigenically matched/mismatched to vaccine strains. Results: The total vaccinated cohort included 12,018 children (N = 1777, 2526, 1564, 1501 and 4650 in cohorts 1-5, respectively). For reverse transcription polymerase chain reaction confirmed influenza of any severity (all strains combined), VE in cohorts 1-5 was 57.8%, 52.9%, 73.4%, 30.3% and 41.4%, respectively, with the lower limit of the 95% confidence interval >0 for all estimates. The proportion of vaccine match for all strains combined in each cohort was 0.9%, 79.3%, 72.5%, 24.1% and 28.6%, respectively. Antibiotic use associated with influenza illness was reduced with IIV4 by 71% in Europe, 36% in Asia Pacific and 59% in Central America. Conclusions: IIV4 prevented influenza in children 6-35 months of age in each of 5 separate influenza seasons in diverse geographical regions. A possible interaction between VE, degree of vaccine match and socioeconomic status was observed. The IIV4 attenuated the severity of breakthrough influenza illness and reduced healthcare utilization, particularly antibiotic use.
- Published
- 2020
44. Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement
- Author
-
Abu-Raya, B. Maertens, K. Edwards, K.M. Omer, S.B. Englund, J.A. Flanagan, K.L. Snape, M.D. Amirthalingam, G. Leuridan, E. Damme, P.V. Papaevangelou, V. Launay, O. Dagan, R. Campins, M. Cavaliere, A.F. Frusca, T. Guidi, S. O'Ryan, M. Heininger, U. Tan, T. Alsuwaidi, A.R. Safadi, M.A. Vilca, L.M. Wanlapakorn, N. Madhi, S.A. Giles, M.L. Prymula, R. Ladhani, S. Martinón-Torres, F. Tan, L. Michelin, L. Scambia, G. Principi, N. Esposito, S. World Association of Infectious Diseases Immunological Disorders (WAidid) the Vaccine Study Group of the European Society of Clinical Microbiology Infectious Diseases (EVASG)
- Abstract
Immunization during pregnancy has been recommended in an increasing number of countries. The aim of this strategy is to protect pregnant women and infants from severe infectious disease, morbidity and mortality and is currently limited to tetanus, inactivated influenza, and pertussis-containing vaccines. There have been recent advancements in the development of vaccines designed primarily for use in pregnant women (respiratory syncytial virus and group B Streptococcus vaccines). Although there is increasing evidence to support vaccination in pregnancy, important gaps in knowledge still exist and need to be addressed by future studies. This collaborative consensus paper provides a review of the current literature on immunization during pregnancy and highlights the gaps in knowledge and a consensus of priorities for future research initiatives, in order to optimize protection for both the mother and the infant. © Copyright © 2020 Abu-Raya, Maertens, Edwards, Omer, Englund, Flanagan, Snape, Amirthalingam, Leuridan, Damme, Papaevangelou, Launay, Dagan, Campins, Cavaliere, Frusca, Guidi, O'Ryan, Heininger, Tan, Alsuwaidi, Safadi, Vilca, Wanlapakorn, Madhi, Giles, Prymula, Ladhani, Martinón-Torres, Tan, Michelin, Scambia, Principi and Esposito.
- Published
- 2020
45. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
- Author
-
Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, and Solozabal M
- Abstract
Purpose Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain. Methods A dynamic transmission model was developed to estimate the number of influenza B cases prevented under TIV and QIV strategies (< 65 years (high risk) and >= 65 years). This model considers cross-protective immunity induced by different lineages of influenza B. The output of the transmission model was used as input for a decision tree model that estimated the economic impact of switching TIV to QIV. The models were populated with Spanish data whenever possible. Deterministic univariate and probabilistic multivariate sensitivity analyses were performed. Results Replacing TIV with QIV in all eligible patients with current vaccine coverage in Spain may have prevented 138,707 influenza B cases per season and, therefore avoided 10,748 outpatient visits, 3,179 hospitalizations and 192 deaths. The replacement could save (sic) 532,768 in outpatient visit costs, (sic) 13 million in hospitalization costs, and (sic) 3 million in costs of influenza-related deaths per year. An additional (sic) 5 million costs associated with productivity loss could be saved per year, from the societal perspective. The budget impact from societal perspective would be (sic) 6.5 million, and the incremental cost-effectiveness ratio (ICER) (sic) 1,527 per quality-adjusted life year (QALY). Sensitivity analyses showed robust results. In additional scenarios, QIV also showed an impact at public health level reducing influenza B related cases, outpatient visits, hospitalizations and deaths. Conclusions Our results show public health and economic benefits for influenza prevention with QIV. It would be an efficient intervention for the Spanish National Health Service with major health benefits especially in the population.65-year.
- Published
- 2020
46. Development and validation of a prediction model for invasive bacterial infections in febrile children at European Emergency Departments: MOFICHE, a prospective observational study
- Author
-
Hagedoorn, N.N. (Nienke N.), Borensztajn, D. (Dorine), Nijman, R.G. (Ruud), Nieboer, D. (Daan), Herberg, J.A. (Jethro Adam), Balode, A. (Anda), Von Both, U. (Ulrich), Carrol, E.D. (Enitan), Eleftheriou, I. (Irini), Emonts, M. (Marieke), Flier, M. (Michiel) van der, Groot, R. (Ronald) de, Kohlmaier, B. (Benno), Lim, E. (Emma), MacOnochie, I.K. (Ian), Martinón-Torres, F. (Federico), Pokorn, M. (Marko), Strle, F. (Franc), Tsolia, M. (Maria), Zavadska, D. (Dace), Zenz, W. (Werner), Levin, M. (Michael), Vermont, C.L. (Clementien), Moll, H.A. (Henriëtte), Hagedoorn, N.N. (Nienke N.), Borensztajn, D. (Dorine), Nijman, R.G. (Ruud), Nieboer, D. (Daan), Herberg, J.A. (Jethro Adam), Balode, A. (Anda), Von Both, U. (Ulrich), Carrol, E.D. (Enitan), Eleftheriou, I. (Irini), Emonts, M. (Marieke), Flier, M. (Michiel) van der, Groot, R. (Ronald) de, Kohlmaier, B. (Benno), Lim, E. (Emma), MacOnochie, I.K. (Ian), Martinón-Torres, F. (Federico), Pokorn, M. (Marko), Strle, F. (Franc), Tsolia, M. (Maria), Zavadska, D. (Dace), Zenz, W. (Werner), Levin, M. (Michael), Vermont, C.L. (Clementien), and Moll, H.A. (Henriëtte)
- Abstract
Objectives: To develop and cross-validate a multivariable clinical prediction model to identify invasive bacterial infections (IBI) and to identify patient groups who might benefit from new biomarkers. Design: Prospective observational study. Setting: 12 emergency departments (EDs) in 8 European countries. Patients: Febrile children aged 0-18 years. Main outcome measures: IBI, defined as bacteraemia, meningitis and bone/joint infection. We derived and cross-validated a model for IBI using variables from the Feverkidstool (clinical symptoms, C reactive protein), neurological signs, non-blanching rash and comorbidity. We assessed discrimination (area under the receiver operating curve) and diagnostic performance at different risk thresholds for IBI: sensitivity, specificity, negative and positive likelihood ratios (LRs). Results: Of 16 268 patients, 135 (0.8%) had an IBI. The discriminative ability of the model was 0.84 (95% CI 0.81 to 0.88) and 0.78 (95% CI 0.74 to 0.82) in pooled cross-validations. The model performed well for the rule-out threshold of 0.1% (sensitivity 0.97 (95% CI 0.93 to 0.99), negative LR 0.1 (95% CI 0.0 to 0.2) and for the rule-in threshold of 2.0% (specificity 0.94 (95% CI 0.94 to 0.95), positive LR 8.4 (95% CI 6.9 to 10.0)). The intermediate thresholds of 0.1%-2.0% performed poorly (ranges: sensitivity 0.59-0.93, negative LR 0.14-0.57, specificity 0.52-0.88, positive LR 1.9-4.8) and comprised 9784 patients (60%). Conclusions: The rule-out threshold of this model has potential to reduce antibiotic treatment while the rule-in threshold could be used to target treatment in febrile children at the ED. In more than half of patients at intermediate risk, sensitive biomarkers could improve identification of IBI and potentially reduce unnecessary antibiotic prescriptions.
- Published
- 2020
- Full Text
- View/download PDF
47. Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood
- Author
-
Zandstra, J. (Judith), van de Geer, A. (Annemarie), Tanck, M.W.T. (Michael), van Stijn-Bringas Dimitriades, D. (Diana), Aarts, C.E.M. (Cathelijn E. M.), Dietz, S.M. (Sanne M.), Bruggen, R. (Robin) van, Schweintzger, N.A. (Nina A.), Zenz, W. (Werner), Emonts, M. (Marieke), Zavadska, D. (Dace), Pokorn, M. (Marko), Usuf, E. (Effua), Moll, H.A. (Henriëtte), Schlapbach, L.J. (Luregn), Carrol, E.D. (Enitan), Paulus, S. (Stephane), Tsolia, M. (Maria), Fink, C. (Colin), Yeung, S. (Shunmay), Shimizu, C. (Chisato), Tremoulet, A. (Adriana), Galassini, R. (Rachel), Wright, V.J. (Victoria), Martinón-Torres, F. (Federico), Herberg, J. (Jethro), Burns, J. (Jane), Levin, M. (Michael), Kuijpers, T.W. (Taco W.), Zandstra, J. (Judith), van de Geer, A. (Annemarie), Tanck, M.W.T. (Michael), van Stijn-Bringas Dimitriades, D. (Diana), Aarts, C.E.M. (Cathelijn E. M.), Dietz, S.M. (Sanne M.), Bruggen, R. (Robin) van, Schweintzger, N.A. (Nina A.), Zenz, W. (Werner), Emonts, M. (Marieke), Zavadska, D. (Dace), Pokorn, M. (Marko), Usuf, E. (Effua), Moll, H.A. (Henriëtte), Schlapbach, L.J. (Luregn), Carrol, E.D. (Enitan), Paulus, S. (Stephane), Tsolia, M. (Maria), Fink, C. (Colin), Yeung, S. (Shunmay), Shimizu, C. (Chisato), Tremoulet, A. (Adriana), Galassini, R. (Rachel), Wright, V.J. (Victoria), Martinón-Torres, F. (Federico), Herberg, J. (Jethro), Burns, J. (Jane), Levin, M. (Michael), and Kuijpers, T.W. (Taco W.)
- Abstract
Background: Kawasaki disease (KD) is a vasculitis of early childhood mimicking several infectious diseases. Differentiation between KD and infectious diseases is essential as KD's most important complication—the development of coronary artery aneurysms (CAA)—can be largely avoided by timely treatment with intravenous immunoglobulins (IVIG). Currently, KD diagnosis is only based on clinical criteria. The aim of this study was to evaluate whether routine C-reactive protein (CRP) and additional inflammatory parameters myeloid-related protein 8/14 (MRP8/14 or S100A8/9) and human neutrophil-derived elastase (HNE) could distinguish KD from infectious diseases. Methods and Results: The cross-sectional study included KD patients and children with proven infections as well as febrile controls. Patients were recruited between July 2006 and December 2018 in Europe and USA. MRP8/14, CRP, and HNE were assessed for their discriminatory ability by multiple logistic regression analysis with backward selection and receiver operator characteristic (ROC) curves. In the discovery cohort, t
- Published
- 2020
- Full Text
- View/download PDF
48. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
- Author
-
van der Vliet, D., primary, Vesikari, T., additional, Sandner, B., additional, Martinón-Torres, F., additional, Muzsay, G., additional, Forsten, A., additional, Adelt, T., additional, Diaz Gonzalez, C., additional, Simko, R., additional, B'Chir, S., additional, Neveu, D., additional, Jordanov, E., additional, and Dhingra, M. S., additional
- Published
- 2021
- Full Text
- View/download PDF
49. Prevención de la enfermedad meningocócica por el serogrupo B mediante una vacuna de 4 componentes
- Author
-
Gil, A., Barranco, D., Batalla, J., Bayas, J.M., Campins, M., Gorrotxategi Gorrotxategi, P., Lluch, J., Martinón-Torres, F., Mellado, M.J., Moreno-Pérez, D., Uriel, B., and Vázquez, J.A.
- Published
- 2014
- Full Text
- View/download PDF
50. PMU34 An Ideal and Sustainable Framework Agreement for the Public Procurement of Vaccines in Spain
- Author
-
Hidalgo-Vega, A., primary, Arrazola Martinez, P., additional, Cuesta Esteve, I., additional, García Rojas, A., additional, Martinón-Torres, F., additional, Redondo Margüello, E., additional, Rivero Cuadrado, A., additional, Tamames Gómez, S., additional, Chávarri Bravo, J., additional, Zozaya, N., additional, and Villaseca, J., additional
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.